BioSpace News Archive

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has issued a CEO Update announcing that the U.S. Food and Drug Administration has denied Breakthrough Therapy Designation for aviptadil.

DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the 4th Annual Evercore ISI HealthCONx Conference.

We have now several clinics activated in the phase III study CONCLUDE and look forward to enrol the first patient in the near term.

Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020, delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients in the future, according to a study being presented next week at the annual meeting of the Radiological Society of North America.

Leading dental implant centre Malo Smiles Toronto and genetic testing company Inagene Diagnostics Inc. are bringing innovation to dental care that will involve less pain during and after procedures, fewer safety risks and complications, and faster recovery times.

Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference.

BD (Becton, Dickinson and Company) today announced Francesca DeMartino has been named senior vice president of investor relations for the company, effective Nov. 29.

Algernon Pharmaceuticals Inc. is pleased to announce that it has received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-IND (Investigational New Drug) meeting for its investigation of NP-120 (Ifenprodil) for the treatment of small cell lung cancer (SCLC).

Nasus Pharma today announced data from its NP-003 study -a two arm double blind placebo controlled study demonstrating that Taffix®, the Company’s innovative nasal powder inhaler that effectively blocks viruses from reaching nasal mucosa, was able to significantly reduce Common Cold and Upper Respiratory Infection and showed a strong positive trend in reducing the risk of COVID infection.

Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021.